Pill A, Pill B: simplified second-line treatment for low-income countries
1 August 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Treatment access
UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030
1 August 2014. Related: Conference reports, Treatment access.
No difference in overall anaemia rate with reduced dose AZT
1 August 2014. Related: Conference reports, Treatment strategies, Treatment access.
Rationalising the paediatric antiretroviral formulary in Malawi
1 August 2014. Related: Conference reports, Treatment access, Paediatric care.
New ARV prescribing guidelines for London (2014)
1 August 2014. Related: Treatment access, Guidelines.
Global update: hepatitis C treatment activism
19 July 2014. Related: Pipeline report, Treatment access, Hepatitis coinfection.
Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed
27 May 2014. Related: Conference reports, Treatment access.
FDA approvals of generic ARVS
24 March 2014. Related: Treatment access.
Dolutegravir approved in Europe
1 February 2014. Related: Antiretrovirals, Treatment access.
BMS to add atazanavir to Patent Pool
1 February 2014. Related: Treatment access.
Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal
1 February 2014. Related: Treatment access.
Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law
1 February 2014. Related: Treatment access.
Obama increases US contribution to Global Fund to $5 billion over three years
1 December 2013. Related: Treatment access.
HIV struggle in South Africa undermined by medicine stockouts and mismanagement
1 December 2013. Related: Treatment access.
Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)
1 October 2013. Related: Treatment strategies, Treatment access, Guidelines.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
From sky high to CHAI* – what needs to be done about dolutegravir pricing?
1 October 2013. Related: Antiretrovirals, Treatment access.
UK pledges £1 billion for Global Fund
1 October 2013. Related: Treatment access.
France pledges $1.4 billion for Global Fund
1 October 2013. Related: Treatment access.
UNAIDS reports new HIV infections are reduced by one-third compared to 2001
1 October 2013. Related: Treatment access.
WHO 2013 guidelines: what about the missing formulations?
25 July 2013. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
Ending global use of d4T: UNITAID to tip market to safer alternatives
25 July 2013. Related: Treatment access, Side effects.
TRIPS extension for least developed countries
25 July 2013. Related: Treatment access.
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
25 July 2013. Related: Antiretrovirals, Treatment access.
Upcoming WHO ART guidelines (2013)
29 May 2013. Related: Treatment access.
Fixed dose combination efavirenz/tenofovir/FTC for South Africa
29 May 2013. Related: Treatment access.
New UNAIDS report highlights progress in the AIDS response in Africa
29 May 2013. Related: Treatment access.
Indian Supreme Court delivers verdict in Novartis case: decision safeguards access to affordable medicines and prevents abusive patenting of medicines
29 May 2013. Related: Treatment access.
FDA approval of generic ARVs
29 May 2013. Related: Treatment access.
New UNITAID grants focus on paediatric HIV, TB and malaria
1 February 2013. Related: Treatment access, Paediatric care, TB coinfection.
Global Fund results continue upward trend
1 February 2013. Related: Treatment access.
Germany extends €200 million annual support to Global Fund until 2016
1 February 2013. Related: Treatment access.
New analysis of country pledges and contributions to the Global Fund
1 February 2013. Related: Treatment access.
Renewal of Indian Global Fund Grant made conditional on government funding for ART
1 February 2013. Related: Treatment access.
MSF and DNDi report highlights importance of research into neglected diseases
1 February 2013. Related: Treatment access.
FDA approval of generic ARVs
1 December 2012. Related: Treatment access.
d4T – time to move on
1 December 2012. Related: Treatment access.
Global Fund provides ART for 4.2 million people: 2012 update
1 December 2012. Related: Treatment access.
$84 million grant to Zimbabwe to reach universal access in 2012
1 December 2012. Related: Treatment access.
Mark Dybul to be the next executive director of the Global Fund
1 December 2012. Related: Treatment access.
US NIH to enforce open access to clincal trial results
1 December 2012. Related: Treatment access.
FDA approval of generic ARVs
1 October 2012. Related: Treatment access.
Free HIV treatment in the UK for all, irrespective of residency status
1 October 2012. Related: Treatment access.
Robin Hood Tax begins in France
1 October 2012. Related: Treatment access.
Novartis case enters Indian Supreme court
1 October 2012. Related: Treatment access.
Online video interviews between researchers and activists
1 October 2012. Related: Conference reports, Antiretrovirals, Treatment access, HIV prevention and transmission, Cure-related research, Other news.
India: Bayer stay order against compulsory licence denied
1 October 2012. Related: Treatment access.
IAS: social and political talks online as web casts
1 August 2012. Related: Conference reports, Treatment access, Treatment advocacy.
FDA approval of generic ARVs
1 August 2012. Related: Treatment access.
Activists protest at IAS for Global Fund to stick to principles
1 August 2012. Related: Treatment access.
EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines
1 August 2012. Related: Treatment access.
US trade deal threatens access to medicines
1 August 2012. Related: Treatment access.
Stavudine (d4T) phase-out festival in Delhi
1 June 2012. Related: Treatment access.
FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US
1 June 2012. Related: Treatment access.
Global action over the challenge to India
2 April 2012. Related: Treatment access.
Why global health activists are fired up about Novartis
1 April 2012. Related: Treatment access.
Obama’s global, domestic & HIV research budget backslides on existing commitments
1 April 2012. Related: Treatment access.
FDA approval of generic ARVs
1 February 2012. Related: Treatment access.
Disastrous warning for global HIV programmes in 2012
1 February 2012. Related: Treatment access.
Janssen block Patent Pool access to darunavir, rilpivirine and etravrine
1 February 2012. Related: Treatment access.
UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria
1 February 2012. Related: Treatment access.
Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager
1 February 2012. Related: Treatment access.
Call to Action on Global Fund restriction to new funding to 2014
1 February 2012. Related: Treatment access.
Analysis of why the Global Fund cancelled Round 11
1 February 2012. Related: Treatment access.